CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT – Nasdaq
CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MITNasdaqBASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on… Continue reading
